Bradley Bostic’s career has been nothing short of extraordinary. As a trailblazer in the healthcare and technology sectors, he’s spent decades reshaping how we approach patient care. From founding hc1 to establishing Health Cloud Capital, Bradley has harnessed the power of data to create innovative solutions that improve patient outcomes while aligning with economic incentives. His story is both a blueprint and a call to action for healthcare leaders to rethink the systems that underpin modern medicine.

Bradley’s inspiration began early, influenced by his father, a banker with a knack for evaluating risk. Conversations with his dad laid the foundation for Bradley’s entrepreneurial mindset. “Everyone has ideas,” Bradley shared, “but unless you bring the right elements together, you aren’t going to succeed.” This principle became his north star, guiding him through ventures ranging from e-commerce to healthcare innovation.

His pivot into healthcare was deeply personal. After losing his mother to colon cancer, Bradley saw firsthand the disjointed and reactive nature of the healthcare system. “She was otherwise healthy, but she never had a colonoscopy recommended,” he recounted. This experience ignited a passion for proactive, patient-centric care, leading him to focus on integrating data to enhance diagnostics and treatment.

Bradley’s vision culminated in hc1, a company leveraging lab data to personalize care. He recognized that laboratory results hold unparalleled potential in healthcare, describing them as “the most powerful dataset across all of healthcare.” By unlocking insights from these results, hc1 ensures patients receive the right tests and treatments at the right time, ultimately saving lives and reducing costs.

However, his journey wasn’t without challenges. Bradley recalls a pivotal conversation with a healthcare CFO who questioned the revenue impact of a system designed to reduce hospital visits. “It was shocking,” Bradley admitted, “but it reinforced the need to align innovation with the economic realities of healthcare.” This realization became the cornerstone of his approach: marrying transformative ideas with sustainable business models.

Bradley’s ecosystem of companies under Health Cloud Capital, including Acumen and DecisionRx, exemplifies this philosophy. Each venture addresses a critical gap in healthcare, from optimizing lab operations to ensuring patients receive medications tailored to their genetic profiles. These innovations are not only improving care but also driving profitability for healthcare providers—a win-win that Bradley believes is essential for lasting change.

His work aligns with the industry’s shift toward value-based care, where providers are rewarded for keeping patients healthy rather than for the volume of services rendered. Bradley sees this as a turning point: “It’s creating the right kind of alignment between payers and providers, focusing on outcomes instead of events.”

Bradley’s optimism about the future of healthcare is infectious. He credits advancements in cloud computing and artificial intelligence as enablers of what he calls a “golden era” in medicine. Yet, he remains grounded, emphasizing the importance of community and mentorship. “Every day, I wake up with a day-one mentality,” he said. “I want to help others achieve their goals faster by sharing what I’ve learned.”

As Bradley continues to lead hc1 and its sister companies, his focus remains clear: creating solutions that are as impactful as they are sustainable. His dedication to innovation, coupled with a deep respect for the human side of healthcare, serves as an inspiration for anyone looking to make a difference in this complex industry.

In Bradley’s words, “If we align technology, economics, and patient care, we can create a future where everyone benefits. That’s not just an aspiration—it’s a responsibility.”

Artificial intelligence has been a buzzword for years, but few leaders in healthcare are truly harnessing its potential to transform how we diagnose, treat, and ultimately save lives. Bradley Bostic, host of BoomBostic Health and CEO of hc1, recently invited Simon Arkell, CEO of Ryght AI, to explore the incredible leaps AI is making in clinical trials and diagnostics. Simon, a former Olympian turned serial entrepreneur, brings a refreshing perspective on AI’s untapped capabilities in healthcare, grounded in years of experience and success.

Simon’s journey from Olympic pole vaulter to AI innovator is remarkable in itself. But it’s his insights into how generative AI can revamp clinical trials that truly set him apart. He explains how AI has evolved, not just as a buzzword but as a game-changing force that redefines what’s possible in healthcare. Ryght AI’s approach is to simplify and accelerate clinical research by connecting all the moving parts involved, creating a platform that benefits from each new advancement in AI without the technical “debt” that usually accompanies such innovation.

One of the most significant obstacles in clinical research is data fragmentation. Many biotech firms lack access to real-time data, making it difficult to connect the right patients with the right trials. Simon elaborates on how Ryght AI leverages generative AI to bridge this gap, creating a network that can process data from various sources, making trial recruitment faster and more precise. Bradley, a strong advocate for personalized care, was quick to highlight the urgent need for such a transformation. “There’s a reason AI is essential here—it could mean years shaved off in bringing life-saving drugs to market,” Bradley emphasized.

Simon’s vision for AI goes beyond mere data processing. He explains that AI enables a more holistic approach, where clinical trials are no longer bound by outdated methods, such as manually matching patient profiles with trials. Instead, AI can predict which clinical trial sites will succeed based on historical data, patient demographics, and existing workloads. This way, clinical trials aren’t just fast-tracked; they’re also more effective. As Simon puts it, “We’re looking to create a future-proof platform that can adapt to new AI models and leverage data without re-engineering the wheel.”

The conversation then shifts to the human element in AI-driven healthcare. Simon recounts how AI, if used correctly, could reduce the burnout that often affects doctors and researchers by automating repetitive tasks and allowing them to focus on direct patient care. He imagines a future where AI doesn’t replace human judgment but enhances it, giving medical professionals the time and data to make better-informed decisions.

One of the key points Simon raised was the necessity of keeping AI adaptable. Ryght AI’s platform sits above the shifting landscape of AI models, allowing it to incorporate the latest and best models without a massive overhaul each time. This adaptability, as he argues, is crucial for any healthcare company looking to stay relevant. In response, Bradley acknowledged the unique challenges and pointed out that “AI in healthcare isn’t just a trend; it’s a strategic advantage for those ready to evolve.”

When discussing the possible drawbacks of AI, both Bradley and Simon agree that regulation will play a major role. AI’s rapid development, while promising, also brings with it concerns about accuracy and accountability. For instance, a misdiagnosis or data error caused by AI could have severe repercussions. To mitigate this, Ryght AI incorporates what Simon calls “human feedback loops,” ensuring that AI-generated insights are validated by experienced professionals. This approach, Simon believes, allows AI to reach its full potential without sidelining the vital human expertise that healthcare...

Regenerative medicine isn’t just a trending topic—it’s reshaping the entire healthcare landscape. In a recent discussion, Bradley Bostic and Chris Gandy tackle this rapidly evolving field, focusing on how it impacts medical professionals, patients, and the healthcare business itself. With rising frustrations among healthcare providers over declining reimbursements and the risk-heavy nature of traditional practices, Chris has found a unique approach to adapt while empowering his clients to make impactful choices.

For those unfamiliar, regenerative medicine emphasizes the body’s ability to heal itself. This includes therapies like peptides, stem cells, and treatments aimed at restoring function without invasive procedures. Chris notes a profound shift: many seasoned surgeons and anesthesiologists are pivoting to regenerative practices, recognizing that the high-stakes environment of Western medicine often comes with shrinking margins and intense liability. "I’ve seen seasoned professionals turn to regenerative medicine, not just for the income streams but for a fresh, proactive approach to healthcare," Chris explains. In his experience, the shift isn’t merely financial—it’s philosophical.

Bradley is quick to agree, underscoring how this approach aligns with the modern medical landscape, where private practices are often absorbed by larger organizations, leading to reduced independence for many physicians. As Chris puts it, the allure of “being able to help people without having to cut them open” is a game-changer. It’s this shift that has led to a boom in practices offering regenerative options, even as traditional models see increased consolidation and constraints.

Chris’s own story highlights the personal side of regenerative medicine. Following a sports injury, he found himself exploring alternative paths to healing—ones that didn’t rely on the typical pharmaceutical or surgical interventions. “I needed to find a way to stay active without compromising my body’s longevity,” he says. His exploration of regenerative techniques has become a lifestyle, encompassing everything from stem cell therapies to cutting-edge physical regimens like hot yoga. This journey has enabled him to help others, particularly former athletes, to find sustainable health solutions that extend far beyond the sports field.

Beyond the physical, Chris also touches on the mental resilience that regenerative medicine brings. He describes the phenomenon where many patients, himself included, find renewed energy and clarity. This aligns well with studies showing that proactive health measures not only improve physical wellness but mental acuity. For Bradley, this isn’t just an emerging trend—it’s a philosophical shift. He adds that individuals willing to adopt preventative, health-focused habits are often better equipped to handle life’s pressures, both personally and professionally.

This type of medicine, however, isn’t accessible to all. Regenerative treatments are largely cash-based, putting them out of reach for many. Yet, Chris argues that the value they bring, in terms of reduced downtime and improved quality of life, is unparalleled. “If you’re considering regenerative options, start by consulting with a trusted physician,” he advises, emphasizing that expertise is paramount in this field, where unqualified practitioners can often get it wrong.

The conversation also delves into the impact of financial literacy on healthcare. Chris helps his clients in the medical field navigate these new waters, often advising on how to make wise choices in both their professional and personal lives. He believes that healthcare providers who are financially empowered make better, more ethical decisions—another reason why regenerative medicine’s business side matters. Bradley sees this blend of finance and medicine as pivotal, as it ensures doctors retain autonomy while maximizing impact.

Bradley and Chris’s discussion is a

In an era where healthcare increasingly embraces personalization, Bradley Bostic and Lisa Huse are at the forefront, advocating for a shift in patient care that’s both effective and tailored. Their conversation isn’t just about innovation; it’s about making healthcare meet the unique needs of each patient. They explore a new kind of patient experience—one where traditional trial-and-error approaches are left behind, replaced by diagnostics and therapies that fit each individual.

Lisa’s extensive experience, particularly in diabetes care with Roche, gives her insights a grounded credibility. She understands that managing diabetes is about more than just medication. As she puts it, “It was about personalization and helping people find their own version of what good looked like.” This isn’t an easy path; the transition from standard methods to personalized care requires shifting entire systems and mindsets, something she and Bradley both passionately advocate for.

When managing diabetes, the challenge goes beyond merely prescribing treatments. Lisa discusses her work with Roche in a world where devices and apps are not always integrated. As she explains, many people face “disparate pieces and parts where one diagnostic product didn't talk to the therapeutic product.” This lack of connectivity can prevent patients from seeing the full picture of their health. It’s here where Lisa saw the potential to change lives—working on models to guide patients toward sustainable behavior changes, which, as she mentions, “feels realistic and something they could accomplish.”

For those navigating diabetes, or any chronic condition, this kind of behavioral support is essential. "Diabetes in many situations is a behavioral disease," Lisa says, stressing that while medication is critical, it isn’t the full solution. She and Bradley explore how success lies in creating a system where patients are motivated by personal goals—like walking a daughter down the aisle—rather than abstract medical advice. The conversation brings into focus the question: How do we enable patients to take control without overwhelming them?

Bradley's interest in this subject isn’t just theoretical. As the founder of hc1, he’s been a transformative figure, guiding his company to become a leader in using AI to analyze lab data, ensuring that each patient gets the treatment they need, at the time they need it. His experience underscores the need for an approach that combines empathy with innovation.

One key topic Lisa highlights is the evolution from clinic-centered care to care at home. Technology is paving the way for home diagnostics and telehealth to improve accessibility and outcomes. As Lisa describes, the future of healthcare is not in prescribing more but in enabling patients to “engage the healthcare community that surrounds you.” It’s a vision where patients work with healthcare professionals in a more collaborative and personalized way—one that doesn’t sacrifice individual needs for a one-size-fits-all solution.

For Lisa and Bradley, the future of healthcare must balance innovation with economic feasibility. Healthcare may be a trillion-dollar industry, but introducing new models of care often meets with financial resistance. As Bradley notes, the industry is a “zero-sum game” where economic incentives are paramount. Without a financial structure that supports innovations like those Lisa champions, the most groundbreaking ideas risk being shelved.

The discussion also underscores the importance of keeping the clinician in the loop. Even with advancements in telehealth and AI, Lisa emphasizes that “diagnosing any condition requires a clinician,” ensuring accuracy and context. This human element, coupled with the power of technology, is where Lisa sees the true potential for change.

As our healthcare system faces shortages of trained...